GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » Quick Ratio

RYTM (Rhythm Pharmaceuticals) Quick Ratio : 3.08 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Rhythm Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2024 was 3.08.

Rhythm Pharmaceuticals has a quick ratio of 3.08. It generally indicates good short-term financial strength.

The historical rank and industry rank for Rhythm Pharmaceuticals's Quick Ratio or its related term are showing as below:

RYTM' s Quick Ratio Range Over the Past 10 Years
Min: 2.36   Med: 7.97   Max: 22.42
Current: 3.08

During the past 10 years, Rhythm Pharmaceuticals's highest Quick Ratio was 22.42. The lowest was 2.36. And the median was 7.97.

RYTM's Quick Ratio is ranked worse than
53.07% of 1496 companies
in the Biotechnology industry
Industry Median: 3.38 vs RYTM: 3.08

Rhythm Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Rhythm Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals Quick Ratio Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.10 7.10 8.83 5.43 3.08

Rhythm Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.43 4.20 6.31 3.34 3.08

Competitive Comparison of Rhythm Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Quick Ratio falls into.


;
;

Rhythm Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Rhythm Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Quick Ratio (A: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(374.2-18.741)/115.517
=3.08

Rhythm Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2024 is calculated as

Quick Ratio (Q: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(374.2-18.741)/115.517
=3.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Pharmaceuticals  (NAS:RYTM) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Rhythm Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Pharmaceuticals Business Description

Traded in Other Exchanges
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Executives
Yann Mazabraud officer: EVP, Head of International C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
Christopher Paul German officer: Corporate Controller & CAO C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Pamela J. Cramer officer: Chief Human Resources Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Joseph Shulman officer: Chief Technical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Hunter C Smith officer: CFO and Treasurer C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820
Jennifer Chien officer: EVP, Head of North America C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
David P Meeker director C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
William T. Roberts officer: Chief Accounting Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Linda Shapiro Manning officer: Chief Medical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Camille L Bedrosian director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nithya Desikan officer: Chief Commercial Officer 82 BAY STATE ROAD, BELMONT MA 02478